Lake Street downgraded Checkpoint Therapeutics (CKPT) to Hold from Buy with a price target of $4.10, down from $7, after Sun Pharma announced it will be acquiring Checkpoint for up to $355M, or $4.10 per share, plus a contingent value right of up to 70c per share. The firm expects no additional bids and for the deal to close in Q2, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CKPT:
- Unusually active option classes on open March 10th
- Checkpoint price target lowered to $4.80 from $9 at D. Boral Capital
- Checkpoint Therapeutics Merges with Sun Pharma for $416M
- Checkpoint Therapeutics initiated with a Buy at D. Boral Capital
- Checkpoint Therapeutics Signs Executive Agreement with CFO
Questions or Comments about the article? Write to editor@tipranks.com